Shots: The approval is based on two P-IIItrials PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine involves assessing of Vyepti (100mg or 300mg) vsPBO in 2076 patients with migraine […]readmore
Tags : Lundbecks